SCHEMBL845026

SCHEMBL845026

O=C(Nc1ccc(/C=C/c2ccc(NC(=O)[C@@H]3CCCN3C(=O)c3cccc4cc[nH]c34)cc2)cc1)[C@@H]1CCCN1C(=O)c1cccc2cc[nH]c12

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
TRPV1 Q8NER1 2/20 0.42
ALDH1A1 P00352 3/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
EP300 Q09472 2/20 0.41
MAPT P10636 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
RHOC P08134 1/20 0.41
RHOA P61586 1/20 0.41
PABPC1 P11940 1/20 0.40
CREBBP Q92793 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL871556 0.92 CYP2C9 (0.38) CYP2C9CYP2C19TRPV1ALDH1A1MAPK1
SCHEMBL13272389 0.89 TRPV1 (0.36) CYP2C9CYP2C19TRPV1ALDH1A1MAPK1
SCHEMBL845039 0.84 TRPV1 (0.51) CYP2C9CYP2C19TRPV1ALDH1A1MAPK1
SCHEMBL845443 0.81 CYP2C9 (0.47) CYP2C9CYP2C19TRPV1ALDH1A1MAPK1
SCHEMBL845008 0.80 ALDH1A1 (0.54) CYP2C9CYP2C19ALDH1A1MAPK1HTT
SCHEMBL844996 0.79 CYP2C9 (0.50) CYP2C9CYP2C19TRPV1ALDH1A1MAPK1
SCHEMBL845257 0.79 TRPV1 (0.48) CYP2C9CYP2C19TRPV1ALDH1A1MAPK1
SCHEMBL845021 0.78 ALDH1A1 (0.53) CYP2C9CYP2C19TRPV1ALDH1A1MAPK1
SCHEMBL872532 0.78 TRPV1 (0.44) CYP2C9CYP2C19TRPV1ALDH1A1MAPK1
SCHEMBL845046 0.78 CYP2C9 (0.46) CYP2C9CYP2C19TRPV1ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143288-B2 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-27 US disclosed
US-8143288-B2 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-27 US disclosed
EP-1893573-B1 INHIBITORS OF HCV REPLICATION BRISTOL MYERS SQUIBB CO (US) 2010-07-21 EP disclosed